News
-
Dupilumab reverses airway inflammation, mucus hypersecretion in type 2 asthma
Lead author Mario Castro, MD, MPH, FCCP, said the VESTIGE trial is one of the first to show that we can reverse the disease process in asthma and substantially improve lung function.
-
CMS decision positively impacts the future of home ventilation coverage
CMS recently released a decision on coverage for noninvasive ventilation devices for patients with COPD, a process that CHEST has been closely involved in.
-
For the neuromuscular disease community, ventilation coverage victory doesn’t carry over
Patient advocate Spero Koulouras said he believes CMS home ventilation coverage criteria for patients with disorders such as ALS are still ambiguous enough that private insurers have interpreted them to deny and delay coverage.
-
SWIFT studies show promise of IL-5-targeted twice-yearly option for severe asthma with an eosinophilic phenotype
Lauren E. Eggert, MD, said depemokimab could be a more convenient therapy choice for both patients and providers.
-
Brensocatib awaits FDA approval for bronchiectasis following ASPEN results
Experts Mark Metersky, MD, FCCP; Pamela J. McShane, MD; and Charles L. Daley, MD, FCCP, discuss the potential clinical implications of addressing inflammation in bronchiectasis—from reduced exacerbations and slowed decline in FEV to improved quality of life.
-
MATINEE shows positive results for mepolizumab in COPD
Experts Frank Sciurba, MD, FCCP, and Gerard J. Criner, MD, FCCP, said clinicians have a second option for treating patients with high type 2 inflammation now that the FDA has approved the drug for those with an eosinophilic phenotype.
-
Study to test efficacy of tezepelumab for treating asthma exacerbations in the emergency department
Diego J. Maselli, MD, FCCP, said the TERAA trial will provide needed evidence on the use of biologics in the acute care setting.
-
Pooled data suggest sotatercept as novel disease-modifying therapy for PAH
Aaron B. Waxman, MD, PhD, FCCP, said he believes the drug will become a first-line therapy option, but questions remain regarding when to initiate treatment.
-
Top-line results from FIBRONEER-ILD point to possible third agent for interstitial lung disease
If the data prove accurate, Barry Shea, MD, said nerandomilast could become the first new treatment for lung fibrosis in more than a decade.
-
Tezepelumab trial demonstrates solid results for treatment of CRSwNP
Joseph K. Han, MD, said the data showed the highest change in sinonasal outcome test scores from baseline compared with any other biologic studies for chronic rhinosinusitis with nasal polyps.
